{
  "docId": "019de073-9e32-71bd-acba-301a2d9cbf00",
  "docSlug": "d469b8223f6f86cb5d6a1f0a99cbce5c",
  "documentTitle": "Aeglea BioTherapeutics | Investor Day Presentation Deck | 28 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 22,
  "pageCount": 28,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "pain_points",
  "function": "diagnose_problem",
  "density": "dense",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9e32-71bd-acba-301a2d9cbf00/22",
  "deckHref": "/decks/019de073-9e32-71bd-acba-301a2d9cbf00",
  "deckJsonHref": "/decks/019de073-9e32-71bd-acba-301a2d9cbf00.json",
  "deckAnchorHref": "/decks/019de073-9e32-71bd-acba-301a2d9cbf00#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.15,
        "y": 0.8
      },
      "kind": "callout",
      "text": "With persistently high tHcy levels, patients remain at risk for serious and life-threatening complications",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b837da87-9dab-4b3d-b706-8a1c6e779b93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.37,
        "w": 0.253,
        "x": 0.535,
        "y": 0.218
      },
      "kind": "image",
      "text": "Hand holding a large number of pills",
      "attrs": null,
      "subkind": "photo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "990331b2-a432-4595-9655-5476bb310fa7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.45,
        "x": 0.06,
        "y": 0.22
      },
      "kind": "list",
      "text": "Compliance with severe dietary restrictions and amino acid supplementation is extremely challenging and represents a lifelong burden. Vitamin B6 is largely ineffective for the majority of patients. Betaine can be associated with both safety and tolerability issues.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "84883ae0-3f4d-4000-9c82-b64873ff98a0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.06,
        "y": 0.635
      },
      "kind": "quote",
      "text": "For patients with Classical Homocystinuria, [the biggest challenge] would be compliance with diet. - U.S. Key Opinion Leader",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dc1f132a-ed35-424e-b84f-2f24b6cb54ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.45,
        "x": 0.535,
        "y": 0.635
      },
      "kind": "quote",
      "text": "To get the family to cope with a very difficult life, and to have them compliant for life ... is a very big challenge. - EU Key Opinion Leader",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fc2de65f-66fb-4ac4-8c20-02005ece260d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.75,
        "x": 0.06,
        "y": 0.05
      },
      "kind": "title",
      "text": "Patients with Classical HCU Live With Both Disease and Treatment Burden",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6769ebf7-2940-4548-a47c-e3d19c222776",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 20,
      "beatId": "5fa22bc5-87f2-4946-9705-fa014d063ae3",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution (Provide relief)",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 20-24 introduce Pegtarviliase as a potential best-in-class treatment and provide an overview of its innovative approach",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 24,
      "from": 20,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "8d7561ed-879a-4cee-9208-d194f7670c57",
      "evidence": "The deck presents Pegtarviliase as a potential best-in-class treatment",
      "position": 1,
      "objective": "Introduce Pegtarviliase as a solution to address the needs of Classical HCU patients",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}